Common Variation in the DIO2 Gene Predicts Baseline Psychological Well-Being and Response to Combination Thyroxine Plus Triiodothyronine Therapy in Hypothyroid Patients
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Introduction: Animal studies suggest that up to 80% of intracellular T3 in the brain is derived from circulating T4 by local deiodination. We hypothesized that in patients on T4 common variants in the deiodinase genes might influence baseline psychological well-being and any improvement on combined T4/T3 without necessarily affecting serum thyroid hormone levels. Methods: We analyzed common variants in the three deiodinase genes vs. baseline psychological morbidity and response to T4/T3 in 552 subjects on T4 from the Weston Area T4 T3 Study (WATTS). Primary outcome was improvement in psychological well-being assessed by the General Health Questionnaire 12 (GHQ-12). Results: The rarer CC genotype of the rs225014 polymorphism in the deiodinase 2 gene (DIO2) was present in 16% of the study population and was associated with worse baseline GHQ scores in patients on T4 (CC vs. TT genotype: 14.1 vs. 12.8, P = 0.03). In addition, this genotype showed greater improvement on T4/T3 therapy compared with T4 only by 2.3 GHQ points at 3 months and 1.4 at 12 months (P = 0.03 for repeated measures ANOVA). This polymorphism had no impact on circulating thyroid hormone levels. Conclusions: Our results require replication but suggest that commonly inherited variation in the DIO2 gene is associated both with impaired baseline psychological well-being on T4 and enhanced response to combination T4/T3 therapy, but did not affect serum thyroid hormone levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779 · cited 12×
“Each C allele was associated with a 49% increase in odds of being a HAD-D case (P 0.01) and as a result caseness was almost twice as great in subjects homozygous for the CC genotype as in subjects with the TT genotype (24 vs. 13%).”
BackgroundMethodInfluentialThe Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657 · cited 8×
“First Published Online February 3, 2009 For editorial see page 1521 Abbreviations: C, Cytosine; fT3, free T3; fT4, free T4; GHQ-12, General Health Questionnaire, 12-question version; HAD, Hospital Anxiety and Depression Scale questionnaire; SNP, single-nucleotide polymorphism; T, thymine; TSQ, thyroid symptom question…”
MethodInfluentialBianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 12×
“However, when analyzed T T 1 2 3 11 12 13 14 15 16 17 18 TC 1 2 3 11 12 13 14 15 16 17 18 C C 1 2 3 11 12 13 14 15 16 17 18 B – TSQ *p = 0.03 T T 1 2 3 3.0 3.1 3.2 3.3 3.4 3.5 TC 1 2 3 3.0 3.1 3.2 3.3 3.4 3.5 C C 1 2 3 3.0 3.1 3.2 3.3 3.4 3.5 C – Satisfaction *p = 0.02 T T 1 2 3 9 10 11 12 13 14 15 T C 1 2 3 9 10 11 1…”
BackgroundMethodInfluentialSelf-citationBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 1×
“However, although in the initial study of combination therapy (T4 and T3), patients treated with the combination appeared to have improved well-being (10), 10 subsequent larger studies failed to confirm this benefit (11–20) and in at least one case demonstrated a large and sustained placebo effect (18).”
BackgroundThyroid hormones, serotonin and mood: of synergy and significance in the adult brain
Bauer, M., Heinz, A., & Whybrow, P. C. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000963 · Cited by 370
Wekking, E. M., Appelhof, B. C., Fliers, E., Schene, A. H., Huyser, J., Tijssen, J. G. P., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02025 · Cited by 299
Grozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A., & Leibovici, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0448 · Cited by 296 · cited 2×
“Metaanalysis of these trials (21) showed no benefit from combination therapy and a carefully controlled study of overreplacement with T4 also failed to show benefit (22).”
BackgroundEscobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118353 · Cited by 287
Escobar-Morreale, H. F., del Rey, F. E., Obregón, M. J., & de Escobar, G. M. (1996) · Endocrinology · doi:10.1210/endo.137.6.8641203 · Cited by 261 · cited 1×
“reported that it was not possible to normalize tissue levels of thyroid hormone (T4 and T3) by replacement with T4 alone (2, 3) or T3 alone (4).”
BackgroundPeeters, R. P., van Toor, H., Klootwijk, W., de Rijke, Y. B., Kuiper, G. G. J. M., Uitterlinden, A. G., & Visser, T. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021592 · Cited by 243
Dentice, M., Bandyopadhyay, A., Gereben, B., Callebaut, I., Christoffolete, M. A., Kim, B. W., Nissim, S., Mornon, J.-P., Zavacki, A. M., Zeöld, A., et al. (2005) · Nature Cell Biology · doi:10.1038/ncb1272 · Cited by 227
Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy
Jonklaas, J. (2008) · JAMA · doi:10.1001/jama.299.7.769 · Cited by 216 · cited 2×
“In humans, patients on T4 monotherapy have a significantly higher serum T4 to T3 ratio for a similar TSH than people with normal thyroid function (5, 6).”
BackgroundWalsh, J. P., Shiels, L., Lim, E. M., Bhagat, C. I., Ward, L. C., Stuckey, B. G. A., Dhaliwal, S. S., Chew, G. T., Bhagat, M. C., & Cussons, A. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030249 · Cited by 210
An association between depression, anxiety and thyroid function – a clinical fact or an artefact?
Engum, A., Bjøro, T., Mykletun, A., & Dahl, A. A. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.01250.x · Cited by 208
Cerebral cortex responds rapidly to thyroid hormones
Leonard, J. L., Kaplan, M. M., Visser, T. J., Silva, J. E., & Larsen, P. R. (1981) · Science · doi:10.1126/science.7291997 · Cited by 206 · cited 1×
“D2 activity is regulated according to local thyroid hormone levels in the brain and other tissues and hence can protect against hypothyroidism at a local level by increasing its activity (34, 35).”
BackgroundIdentification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis
Meulenbelt, I., Min, J. L., Bos, S., Riyazi, N., Houwing-Duistermaat, J. J., van der Wijk, H.-J., Kroon, H. M., Nakajima, M., Ikegawa, S., Uitterlinden, A. G., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn082 · Cited by 206
Canani, L. H., Capp, C., Dora, J. M., Meyer, E. L. S., Wagner, M. S., Harney, J. W., Larsen, P. R., Gross, J. L., Bianco, A. C., & Maia, A. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1977 · Cited by 204
The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population
Flynn, R. W. V., MacDonald, T. M., Morris, A. D., Jung, R. T., & Leese, G. P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032089 · Cited by 196 · cited 1×
“Up to 3% of the population in Western countries is on thyroid hormone replacement (1), the majority on T4 alone.”
BackgroundClyde, P. W., Harari, A. E., Getka, E. J., & Shakir, K. M. M. (2003) · JAMA · doi:10.1001/jama.290.22.2952 · Cited by 195
Appelhof, B. C., Fliers, E., Wekking, E. M., Schene, A. H., Huyser, J., Tijssen, J. G. P., Endert, E., van Weert, H. C. P. M., & Wiersinga, W. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2111 · Cited by 183
Escobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00007 · Cited by 182
Sawka, A. M., Gerstein, H. C., Marriott, M. J., MacQueen, G. M., & Joffe, R. T. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030139 · Cited by 175
Walsh, J. P., Ward, L. C., Burke, V., Bhagat, C. I., Shiels, L., Henley, D., Gillett, M. J., Gilbert, R., Tanner, M., & Stuckey, B. G. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0099 · Cited by 164
Gereben, B., Goncalves, C., Harney, J. W., Larsen, P. R., & Bianco, A. C. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.11.0558 · Cited by 161
Panicker, V., Cluett, C., Shields, B., Murray, A., Parnell, K. S., Perry, J. R. B., Weedon, M. N., Singleton, A., Hernandez, D., Evans, J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0397 · Cited by 155
Self-citationSiegmund, W., Spieker, K., Weike, A. I., Giessmann, T., Modess, C., Dabers, T., Kirsch, G., Sänger, E., Engel, G., Hamm, A. O., et al. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02050.x · Cited by 152
Saravanan, P., Simmons, D. J., Greenwood, R., Peters, T. J., & Dayan, C. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1672 · Cited by 136 · cited 5×
“The study design has been previously described (18), but briefly, subjects on a stable dose of T4 therapy 100 g or more per day were recruited from 28 primary care practices in the Weston-superMare and Bristol areas of the United Kingdom and randomized to either combination T4/T3 therapy (original dose minus 50 g of T…”
BackgroundMethodInfluentialSelf-citationA comparison of the validity of GHQ-12 and CHQ-12 in Chinese primary care patients in Manchester
Pan, P.-C., & Goldberg, D. P. (1990) · Psychological Medicine · doi:10.1017/s003329170003662x · Cited by 125
Silva, J. E., & Larsen, P. R. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110699 · Cited by 119
Bunevicius, R., Jakubonien, N., Jurkevicius, R., Cernicat, J., Lašas, L., & Prange, A. J. (2002) · Endocrine · doi:10.1385/endo:18:2:129 · Cited by 111
de Jong, F. J., Peeters, R. P., den Heijer, T., van der Deure, W. M., Hofman, A., Uitterlinden, A. G., Visser, T. J., & Breteler, M. M. B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1331 · Cited by 110
Peeters, R. P., van den Beld, A. W., Attalki, H., Toor, H. V., de Rijke, Y. B., Kuiper, G. G. J. M., Lamberts, S. W. J., Janssen, J. A. M. J. L., Uitterlinden, A. G., & Visser, T. J. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00571.2004 · Cited by 108
Appelhof, B. C., Peeters, R. P., Wiersinga, W. M., Visser, T. J., Wekking, E. M., Huyser, J., Schene, A. H., Tijssen, J. G. P., Hoogendijk, W. J. G., & Fliers, E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0451 · Cited by 91
Rodriguez, T., Lavis, V. R., Meininger, J. C., Kapadia, A. S., & Stafford, L. F. (2005) · Endocrine Practice · doi:10.4158/ep.11.4.223 · Cited by 80
Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations
Woeber, K. A. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03343972 · Cited by 67 · cited 4×
“In humans, patients on T4 monotherapy have a significantly higher serum T4 to T3 ratio for a similar TSH than people with normal thyroid function (5, 6).”
BackgroundInfluentialDissatisfaction with thyroxine therapy — could the patients be right?
Walsh, J. P. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00209-6 · Cited by 49
Escobar-Morreale, H. F., Obregón, M.-J., del Rey, F. E., & de Escobar, G. M. (1999) · Biochimie · doi:10.1016/s0300-9084(99)80095-9 · Cited by 48
TSH may not be a good marker for adequate thyroid hormone replacement therapy
Alevizaki, M., Mantzou, E., Cimponeriu, A. T., Alevizaki, C. C., & Koutras, D. A. (2005) · Wiener klinische Wochenschrift · doi:10.1007/s00508-005-0421-0 · Cited by 34
Research works printed but not linked: 1
- Levitt, 2002, T4 plus T3 for hypothyroidism: a double-blind comparison with usual T4, 4
Cited by
Thyroid Hormone Regulation of Metabolism
Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00030.2013 · Cited by 2,421
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Another population who might potentially benefit from combination therapy is those patients who have the specific DIO2 polymorphism DIO2-Thr92Ala (390), although low serum T3 levels have not been documented in this subpopulation, and abnormal D2 activity has not been con- firmed in this population either.”
InfluentialGarber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
“Why do some patients prefer combination therapy to Lthyroxine monotherapy (133)? Some insight into the latter question may be gained from a large-scale study of L-thyroxine and L-triiodothyronine combination therapy in which different responses were observed in patients with different genetic subtypes of type 2 deiodi…”
Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
Metadata
- Authors
- Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M.
- Affiliations
- The University of Western Australia (AU)
- University of Bristol (GB)
- Royal Devon and Exeter Hospital (GB)
- University of Exeter (GB)
- Corresponding author
- Dayan, Colin M.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-05-01
- Volume
- 94
- Issue
- 5
- Pages
- 1623-1629
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2059487357
- Cited by
- 327
- References
- 39
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 10 · 2023: 23 · 2022: 27 · 2021: 23 · 2020: 15 · 2019: 25 · 2018: 22 · 2017: 21 · 2016: 25 · 2015: 22 · 2014: 19 · 2013: 21 · 2012: 21
- FWCI
- 12.34
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- deiodinase 2, triiodothyronine, thyroxine, hypothyroidism, combination thyroid hormone therapy, genetic polymorphism, psychological well-being, treatment response, GHQ-12, serum thyroid hormones
- MeSH terms
- Iodothyronine Deiodinase Type II, Adult, DNA, Female, Genotype, Health Status, Humans, Hypothyroidism, Iodide Peroxidase, Male, Polymorphism, Genetic, Predictive Value of Tests, Psychometrics, Surveys and Questionnaires, Thyroid Function Tests, Thyrotropin, Thyroxine, Triiodothyronine, Genetic Variation, Hormone Replacement Therapy, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.